Searchable abstracts of presentations at key conferences in endocrinology

ea0098c24 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

68Ga-DOTATATE/18F-FDG dual PET: Utility of the NETPET score in management of G2-3 WD NENs

Nunez Jose E. , Chan David L. , Kulanthaivelu Roshini , Murad Vanessa , Singh Simron , Metser Ur

Background: The clinical heterogeneity of G2 and G3 well-differentiated GEP-NENs make it difficult to choose an effective treatment plan, highlighting the need of molecular imaging in the treatment of NETs patients. It has been suggested that a dual-tracer 68Ga-DOTATATE/18F-FDG grading scoring system could be a useful imaging biomarker. This pilot study aims to validate the prior observation from Chan et al. (BJC 2022) of variability in NETPET scores in G2-G3 WD GEP NENs and a...

ea0089c30 | Clinical – Surgery/Applied Pathology | NANETS2022

Liver-Directed Therapy of Neuroendocrine Liver Metastases

Meloche-Dumas Leamarie , Mercier Frederic , Barabash Victoria , Law Calvin , Coburn Natalie , Singh Simron , Myrehaug Sten , Chan Wing , Hallet Julie

Background: The optimal therapy sequencing for metastatic neuroendocrine tumors (NETs) remains undefined. Recent advances in systemic therapies may have changed approaches. Better understanding in patterns of care is necessary to assess and design treatment strategies. We examined the use of factors associated with liver-directed therapy over time.Methods: We conducted a population-based study of metastatic NETs over 2000-2019. Outcomes were use of liver...

ea0098c49 | Clinical – Surgery/Applied Pathology | NANETS2023

Post-procedure outcomes of liver-directed therapy of neuroendocrine liver metastases

Meloche-Dumas Leamarie , Mercier Frederic , Barabash Victoria , Law Calvin , Singh Simron , Myrehaug Sten , Chan Wing , Hallet Julie

Background: While there have been major advances in the care of neuroendocrine tumors (NETs), there is still no widely adopted therapeutic sequencing in metastatic NETs. The roles and benefits of locoregional treatments need reassessment, in order to define a modern therapeutic algorithm. We examined contemporary short-term outcomes of liver-directed therapy for metastatic NETs.Methods: We conducted a population-based retrospective cohort study of patien...

ea0098p9 | Population Science | NANETS2023

Contemporary incidence and survival of lung neuroendocrine neoplasms: a population-based study

Rousseau Mathieu , Wakeam Elliott , Singh Simron , Myrehaug Sten , Law Calvin , Barabash Victoria , C Chan Wing , Hallet Julie

Background: While the epidemiology of overall and gastrointestinal neuroendocrine neoplasms (NENs) has been reported, data specific to lung NENs remain scarce. Such understanding is crucial in designing tailored strategies to improve care and outcomes. We examined the incidence, overall survival (OS), and disease-specific death (DS-deaths) for lung NENs.Methods: We conducted a population-based retrospective cohort study of adult patients with incident lu...

ea0098t11 | Trials In Progress | NANETS2023

NET RETREAT: a Phase II Study of 177Lutetium-Dotatate Retreatment vs. Everolimus in Metastatic/Unresectable Midgut NET

Chauhan Aman , O'Callaghan Chris , Myrehaug Sten , Bodei Lisa , Kunz Pamela , Dasari Arvind , Strosberg Jonathan , Alexander Stefanie , Cheung Winson , Singh Simron

Background: 177Lu-DOTATATE is an FDA and Health Canada-approved treatment option for metastatic, progressive GEPNET patients. 177Lu-DOTATATE is now often considered the treatment of choice for small bowel/midgut patients who have progressed on somatostatin analogs (SSA). Despite 177Lu- DOTATATE’s impressive disease stabilization, many patients will eventually progress. Progression after prior use of PRRT does not necessarily render these tumors resistant to future PRRT tr...

ea0081p646 | Endocrine-Related Cancer | ECE2022

Methodology of the SORENTO clinical trial: assessing the efficacy and safety of high exposure octreotide subcutaneous depot in patients with GEP-NETs

Ferone Diego , Capdevilla Jaume , Ang Chan Jennifer , de Herder Wouter W , Halperin Daniel , Mailman Josh , Singh Simron , Dorkhan Mozhgan , Hellstrom Lisa , Svedberg Agneta , Tiberg Fredrik

Background: Somatostatin receptor ligands (SRLs) are first-line standard-of-care therapies for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), showing efficacy in tumour and symptom control with an established safety profile. However, disease progression may occur despite standard-dose SRL treatment, requiring more aggressive and toxic treatments. Retrospective/non-randomized data suggest higher-dose SRLs may benefit patients with GEP-NETs who do not respond to stand...

ea0089c1 | Clinical – Chemo/SSA/Biologics | NANETS2022

Progression-Free Survival in Patients with Bronchopulmonary Neuroendocrine Tumors Treated with Lanreotide or Placebo: Adjustment for Crossover Effects in Placebo Arm

Singh Simron , Buikhuisen Wieneke , Capdevila Jaume , Caplin Martyn E , Grohe Christian , Horsch Dieter , Raderer Markus , Reidy-Lagunes Diane , Wolin Edward M , Pommie Christelle , Mai Truong Xuan , Baudin Eric

Background: SPINET was a phase 3 trial (NCT02683941) in patients with well-differentiated, advanced bronchopulmonary neuroendocrine tumors (NETs; typical and atypical carcinoids [TCs and ACs]). During the double-blind (DB) period, patients were randomized (2:1) to receive lanreotide autogel/depot (LAN; 120 mg) or placebo (PBO) every 28 days; in the optional open-label (OL) phase, all patients received LAN. Recruitment was stopped early due to slow accrual; all eligible patient...

ea0098b3 | Basic Science | NANETS2023

Translational biomarkers in G2-3 NENs: Analysis from NET-001 and NET-002 trials

Nunez Jose E. , Bruce Jeffrey , Danesh Arnavaz , Chan David L. , Rodriguez-Freixinos Victor , Hallet Julie , Myrehaug Sten , Law Calvin , Pugh Trevor , Singh Simron

Background: The treatment of neuroendocrine neoplasms (NENs) of higher grade remains a dilemma. In these patients the role of immunotherapy is still unclear and predictive biomarkers are an unmet need. Herein, we present a revised translational analysis of the NET001 and NET002 (NCT03278405, NCT03278379) clinical trials.Methods: Patients with advanced WHO G2-3 NENs who had a gastroenteropancreatic (GEP) or a bronchial primary (excluding typical carcinoid...

ea0098t1 | Trials In Progress | NANETS2023

ACTION-1: A randomized Phase Ib/3 trial of RYZ101 compared with SoC in SSTR+ well-differentiated GEP-NET with progression following Lu-177 SSA

Hope Thomas A. , Halperin Daniel , Strosberg Jonathan , Jacene Heather , E.T. Tesselaar Margot , Kunz Pamela L. , Ferreira Denis , Li Joanne , Ma Kimberly , Rearden Jessica , Moran Susan , Singh Simron

Background: Well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are commonly characterized by high-density expression of somatostatin receptors (SSTRs), which can be targeted by radiopharmaceutical therapy (RPT) via radiolabeled somatostatin analogues (SSAs). RYZ101 (225Ac-DOTATATE) is a first-in-class, highly potent alpha-emitting RPT being developed for the treatment of SSTR+ solid tumors. Alpha-particles (such as those emitted by 225<...

ea0089p4 | Population Science | NANETS2022

Carcinoid Heart Disease in Patients Diagnosed with Small Bowel and Lung Neuroendocrine Tumors

MD, MSc Julie Hallet , MD, MPH Katrina Duncan , MD, MPH Simron Singh , MSc Victoria Barabash , MD Shaheeda Ahmed , MD Sten Myrehaug , MD, MPH Natalie Coburn , MD, MPH Calvin Law

Background: Carcinoid heart disease (CHD) is a complication of neuroendocrine tumors (NETs). While its pathophysiology and manifestations are described, little is known about its occurrence in all patients diagnosed with NETs. We examined the occurrence of CHD and explored the use of echocardiography after diagnosis of NET.Methods: We conducted a population-based retrospective cohort study of adults diagnosed with small bowel and lung NETs (2000-2019). C...